Paradox Immunotherapeutics is an pharmaceutical company developing immunotherapies for rare diseases using a proven-successful immunotherapy drug design platform. We design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. Our team has a successful history in designing drug candidates for amyloidosis and taking them from bench to bedside. Using the same platform technology, our lead candidate includes a potential treatment for immunoglobulin light chain (AL) cardiac amyloidosis. Their other discovery pipelines include treatments for chronic renal failure and neurodegenerative diseases. With a team of experts in immunotherapy drug design, they possess an orphan drug discovery platform, termed "The PARADOX Platform" for the potential treatment of ~30 rare diseases, a platform technology which has already sparked the interest of major players in the pharmaceutical industry.